Trodelvy® Significantly Improved OS In Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients In TROPiCS-02 Study September 13, 2022
Adagrasib +/- cetuximab demonstrates promising clinical efficacy and favorable tolerability in heavily pretreated CRC patients with KRASG12C mutation September 13, 2022
Kisqali® Adds One More Year Of Survival Benefit For Broadest Set Of Patients, Including Those With Aggressive HR+/HER2- Advanced Breast Cancer September 13, 2022
Long-term data from the Ph 3 PRIMA study showed Zejula (niraparib) maintaining a sustained and clinically meaningful PFS benefit in 1L ovarian cancer patients September 13, 2022
Lynparza +/- bevacizumab demonstrates clinically meaningful survival benefit in 1L advanced ovarian cancer across PAOLA-1 and SOLO-1 Ph 3 trials September 13, 2022
Camrelizumab + Rivoceranib (Apatinib) Significantly Prolonged OS & PFS vs Sorafenib in Patients with uHCC in a Multinational Ph 3 Trial September 13, 2022
Results From Ph 3 LEAP-002 Trial of KEYTRUDA® + LENVIMA® Versus LENVIMA Monotherapy in Patients With uHCC presented September 13, 2022
Tislelizumab demonstrated efficacy and tolerability in 1L advanced liver cancer in Ph 3 RATIONALE 301 trial September 13, 2022
DS-7300 Continues to Show Promising Durable Response in Patients with Several Types of Advanced Cancer September 13, 2022
Interim clinical data of RLY-4008 from Ph 1/2 clinical trial in patients with FGFR2-altered CCA and multiple other solid tumors announced September 13, 2022
Updated Findings from the Ph 2 SUMMIT Basket Trial of Neratinib for HER2-Mutant, Recurrent/Metastatic Cervical Cancer presented September 13, 2022
Patient-Reported Outcomes with Mirvetuximab vs Chemo in FORWARD I Study Reinforces Differentiated Tolerability Profile September 13, 2022
Rubraca® (Rucaparib) As 1L Maintenance Treatment Improves PFS In Women With Advanced Ovarian Cancer Across Disease Risk Subgroups September 13, 2022
KEYTRUDA + Chemo Showed Sustained OS Benefit vs Chemo Alone in in KEYNOTE-189 and KEYNOTE-407 trials for mNSCLC September 13, 2022
Tagrisso demonstrated 5.5-year mDFS in the adjuvant treatment of patients with EGFR-mutated lung cancer September 13, 2022
Imfinzi and tremelimumab with chemotherapy demonstrated sustained OS benefit in mNSCLC September 13, 2022
Enhertu continues to demonstrate clinically meaningful tumour response in patients with HER2-mutant mNSCLC September 13, 2022
Trifluridine/tipiracil + bevacizumab showed a statistically significant OS improvement vs trifluridine/tipiracil alone in Ph 3 trial in mCRC patients September 13, 2022
Positive Initial Ph 2 Data in Late-Line Solid Tumor Patients Treated With KRAS-Directed Immunotherapy (SLATE) announced September 13, 2022
Positive data announced from multiple expansion cohorts of Ph 1 trial of fianlimab and Libtayo® (cemiplimab) in advanced melanoma September 13, 2022
Positive early data announced for ubamatamab (REGN4018; MUC16xCD3) in recurrent ovarian cancer and REGN5093 (METxMET) in MET-altered advanced NSCLC September 13, 2022
Positive Neoadjuvant Libtayo® (cemiplimab) Monotherapy Data in Resectable CSCC Published in NEJM September 13, 2022
Results of Clinical Trial Investigating PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA and PADCEV as Monotherapy in 1L Advanced Urothelial Cancer September 13, 2022
FAILED TRIAL: Ph 2 SELECT trial of vopratelimab + pimivalimab combination vs pimivalimab alone did not meet its primary endpoint of mean tumor change in in TISvopra Biomarker-Selected 2L NSCLC Patients September 7, 2022
Ph 3 CodeBreaK 200 trial of LUMAKRAS® (sotorasib) met its primary endpoint of PFS improvement over SoC chemotherapy in KRAS G12C-Mutated NSCLC September 7, 2022
